Skip to main content
  • News in Review

    Early Anti-VEGF Fails to Improve VA in NPDR

    Add to My Bookmarks

    Download PDF

    When is it appropriate to use aflibercept for patients with nonpro­liferative diabetic retinopathy (NPDR) but no center-involved diabetic mac- ular edema (CI-DME)? Results from the DRCR.net Protocol W indicate that the best strategy is to regularly monitor patients and initiate treatment with aflibercept (Eylea) only when vision-threatening complications develop.1

    The researchers investigated the effects of early aflibercept on VA and the rate of vision-threatening complica­tions in patients with moderate to severe NPDR. Although anti-VEGF treatment reduced the risk of progres­sion to proliferative DR and CI-DME with vision loss, the preventive in­jections failed to produce better VA outcomes than sham treatment.

    Mild nonproliferative diabetic retinopathy.

    TOO EARLY TO TREAT. Based on the study’s findings, this patient with mild NPDR should not be treated prophylactically with aflibercept. This image was originally published in the ASRS Retina Image Bank. Carolyn Daley. Mild Nonproliferative Diabetic Retinopathy. Retina Image Bank. 2019; Image Number 28819. © The American Society of Retina Specialists.

    Study rationale. Although anti- VEGF agents are used in patients with proliferative diabetic retinopathy and CI-DME with vision loss, some physicians use them for prophylaxis in patients with NPDR, said Raj Maturi, MD, at Indiana University School of Medicine and Retina Partners Midwest in Indianapolis. Dr. Maturi also served as protocol chair for the study.

    Study specifics. This multicenter study involved 328 adults (399 eyes) with moderate to severe NPDR without CI-DME. Half of the eyes were injected with aflibercept, the other half with sham. All eyes received injections at one, two, and four months after enroll­ment, and then every four months for the rest of the first two years. Preventive treatment with aflibercept was given every four months until the four-year mark except in those whose NPDR im­proved to mild disease. This allowed the researchers to assess the rate of disease progression and the difference in VA between the two groups.

    Risk of progression. The researchers found that the four-year cumulative risk of developing proliferative DR or CI-DME with vision loss was lower in the anti-VEGF group than in the sham group (33.9% vs. 56.9%; p < .001).

    Anatomic benefit and VA. The anti-VEGF therapy slowed disease pro­gression, as measured by the diabetic retinopathy severity scale. However, no differences in VA emerged between the two groups after four years.

    Monitoring is essential. Given these findings, ophthalmologists are advised to regularly monitor patients and promptly treat those who progress to proliferative disease or develop DME, Dr. Maturi said. At this time, however, prophylactic treatment is “not gener­ally warranted” for patients who have NPDR without CI-DME, the investiga­tors wrote.

    —Christos Evangelou, PhD

    ___________________________

    1 Maturi RK et al. JAMA. 2023;329(5):376-385.

    ___________________________

    Relevant financial disclosures: Dr. Maturi—None.

    For full disclosures and the disclosure key, see below.

    Full Financial Disclosures

    Dr. Breazzano DRCR Network: S; Eyepoint: S; Ocuterra: S; Ophthea: S; Oxurion: S.

    Dr. Klink Dutch Research Council: S; European Union: S; Friends Foundation of the Netherlands Institute for Neuroscience: S; Human Brain Project: S.

    Dr. Maturi Allegro: C,S; Allergan: C,S; Allgenesis: C; AiViva: C; Boehringer Ingelheim: S; Clearside: S; Eli Lilly: C; Dutch Ophthalmic: C; Gemini: S; Genentech: S; Graybug: S; Gyroscope: S; KalVista: S; Jaeb Center for Health Research: C; NeuroTech: C; NGM Biopharmaceuticals: S; Novartis: C; Opthea: S; Ribomic: S; Samsung Bioepis: S; Santen: S; Senju: S; ThromboGenics: S; Unity: C,S.

    Dr. Moulton NEI: S; U.S. Department of Veterans Affairs: S.

    Disclosure Category

    Code

    Description
    Consultant/Advisor C Consultant fee, paid advisory boards, or fees for attending a meeting.
    Employee E Hired to work for compensation or received a W2 from a company.
    Employee, executive role EE Hired to work in an executive role for compensation or received a W2 from a company.
    Owner of company EO Ownership or controlling interest in a company, other than stock.
    Independent contractor I Contracted work, including contracted research.
    Lecture fees/Speakers bureau L Lecture fees or honoraria, travel fees or reimbursements when speaking at the invitation of a commercial company.
    Patents/Royalty P Beneficiary of patents and/or royalties for intellectual property.
    Equity/Stock/Stock options holder, private corporation PS Equity ownership, stock and/or stock options in privately owned firms, excluding mutual funds.
    Grant support S Grant support or other financial support from all sources, including research support from government agencies (e.g., NIH), foundations, device manufacturers, and\or pharmaceutical companies. Research funding should be disclosed by the principal or named investigator even if your institution receives the grant and manages the funds.
    Stock options, public or private corporation SO Stock options in a public or private company.
    Equity/Stock holder, public corporation US Equity ownership or stock in publicly traded firms, excluding mutual funds (listed on the stock exchange).

     

    More from this month’s News in Review